Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Kaufman, J.L. (Jonathan L.); Dimopoulos, M.A. (Meletios A.); White, D.J. (Darrell J.); Benboubker, L. (Lotfi); Cook, G. (Gordon); Leiba, M. (Merav); Morton, J. (James); Takezako, N. (Naoki); Kim, K. (Kihyun); Moreau, P. (Philippe); Sutherland, H.J. (Heather J.); Magen, H. (Hila); Iida, S. (Shinsuke); Kim, J.S. (Jin Sheok); Prince, H.M. (H. Miles); Cochrane, T. (Tara); Oriol, A. (Albert); O’Rourke, L. (Lisa); Trivedi, S. (Sonali); Casneuf, T. (Tineke); Krevvata, M. (Maria); Ukropec, J. (Jon); Kobos, R. (Rachel); Avet-Loiseau, H. (Herve); Usmani, S.Z. (Saad Z.); San-Miguel, J.F. (Jesús F.)

Issue Date:

2020

ISSN:

2044-5385

Editorial note:

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Citation:

Kaufman, J.L. (Jonathan L.); Dimopoulos, M.A. (Meletios A.); White, D.J. (Darrell J.); et al. "Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX". Blood Cancer Journal. 10 (111), 2020,

Abstract

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10–5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk.

URI:

https://hdl.handle.net/10171/65790

DOI:

10.1038/s41408-020-00375-2

Appears in Collections:

DA - CIMA - Hemato-oncología - Mieloma - Artículos de Revista

Files in This Item: